APA (7th ed.) Citation

M, G., JP, M., S, P., M, S., C, L., M, G., . . . J, M. (2024). Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy. Cancers, 16(9), . https://doi.org/10.3390/cancers16091735

Chicago Style (17th ed.) Citation

M, Gorostegui, et al. "Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy." Cancers 16, no. 9 (2024). https://doi.org/10.3390/cancers16091735.

MLA (9th ed.) Citation

M, Gorostegui, et al. "Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy." Cancers, vol. 16, no. 9, 2024, https://doi.org/10.3390/cancers16091735.